Identifying and Validating a Combined mRNA and MicroRNA Signature in Response to Imatinib Treatment in a Chronic Myeloid Leukemia Cell Line

Imatinib, a targeted tyrosine kinase inhibitor, is the gold standard for managing chronic myeloid leukemia (CML). Despite its wide application, imatinib resistance occurs in 20–30% of individuals with CML. Multiple potential biomarkers have been identified to predict imatinib response; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhutra, Steven, Lenkala, Divya, LaCroix, Bonnie, Ye, Meng, Huang, R. Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266614/
https://www.ncbi.nlm.nih.gov/pubmed/25506832
http://dx.doi.org/10.1371/journal.pone.0115003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266614/
https://www.ncbi.nlm.nih.gov/pubmed/25506832
http://dx.doi.org/10.1371/journal.pone.0115003

Ejemplares similares